Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, shares an analysis of the Phase III placebo-controlled IMerge trial (NCT02598661), assessing the efficacy of imetelstat in patients with transfusion-dependent low-risk myelodysplastic syndromes (LR-MDS) who are relapsed/refractory (R/R) to erythropoiesis-stimulating agents (ESAs). The trial revealed an 18% sustained transfusion-independence rate and favorable drug tolerability. Additionally, there was a decrease in mutational burden, suggesting the disease-modifying potential of the drug. Imetelstat is currently undergoing approval review for second-line treatment in LR-MDS. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.